Recent Finacing
Recent Raise
AntriaBio develops proprietary microsphere formulation and manufacturing for extended‑release therapeutics, advancing AB101, a once‑weekly basal insulin, into Phase 1 trials for diabetes.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
